Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
radium-223 + enzalutamide
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Radium-223 + enzalutamide is a combination therapy under clinical development for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. Radium-223 dichloride is a radiopharmaceutical that mimics calcium and selectively targets bone metastases, delivering alpha particle radiation that induces double-stranded DNA breaks in cancer cells, leading to cell death. Enzalutamide is an androgen receptor inhibitor that blocks the action of male hormones (androgens), thereby inhibiting prostate cancer cell growth and survival. The combination leverages their distinct mechanisms—radium-223’s targeted radiotherapy and enzalutamide’s hormonal blockade—to improve outcomes and potentially delay resistance to treatment. Recent phase 3 trial data show significant improvements in radiological progression-free survival (rPFS) and overall survival (OS) compared to monotherapy[1][2][5][6].
- Brand names
- XofigoXtandi
- Other names
- radium-223 dichlorideradium223 dichlorideradium 223 dichlorideenzalutamide
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on radium-223 + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on radium-223 + enzalutamide.